CoChat

Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis. Knockdown of hepatic FMO3 in LDL receptor knockout mice using an antisense oligonucleotide resulted in decreased circulating TMAO levels and atherosclerosis. Surprisingly, we also observed significant decreases in hepatic lipids and in levels of plasma lipids, ketone bodies, glucose, and insulin. FMO3 overexpression in transgenic mice, on the other hand, increased hepatic and plasma lipids. Global gene expression analyses suggested that these effects of FMO3 on lipogenesis and gluconeogenesis may be mediated through the PPARα and Kruppel-like factor 15 pathways. In vivo and in vitro results were consistent with the concept that the effects were mediated directly by FMO3 rather than trimethylamine/TMAO; in particular, overexpression of FMO3 in the human hepatoma cell line, Hep3B, resulted in significantly increased glucose secretion and lipogenesis. Our results indicate a major role for FMO3 in modulating glucose and lipid homeostasis in vivo, and they suggest that pharmacologic inhibition of FMO3 to reduce TMAO levels would be confounded by metabolic interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m051680

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 FMO3 knockdown in LDLRKO mice leads to decreased hepatic FMO3 protein and activity levels, altered plasma TMAO and TMA levels, and decreased adiposity. A: Liver FMO3 protein levels of mice treated with saline (S), control ASO (control), or FMO3 ASO (FMO3) were determined by immunoblotting. B: Liver FMO activity (n = 6 for each group) was determined using TMA as the substrate. Plasma TMAO (C) and TMA (D) levels were determined by mass spectrometry (n = 12 for each group). Body weight (E) and percent weight of four fat pads (gonadal, retroperitoneal, subcutaneous, and mesentery fat pads) (F) were normalized by the body weight (n = 12 for each group). Student's t -test: # P < 0.05 as compared with the saline group; * P < 0.05 as compared with the control ASO group. ANOVA: & P < 0.05 between the means of the three treatment groups.
Fig. 1 FMO3 knockdown in LDLRKO mice leads to decreased hepatic FMO3 protein and activity levels, altered plasma TMAO and TMA levels, and decreased adiposity. A: Liver FMO3 protein levels of mice treated with saline (S), control ASO (control), or FMO3 ASO (FMO3) were determined by immunoblotting. B: Liver FMO activity (n = 6 for each group) was determined using TMA as the substrate. Plasma TMAO (C) and TMA (D) levels were determined by mass spectrometry (n = 12 for each group). Body weight (E) and percent weight of four fat pads (gonadal, retroperitoneal, subcutaneous, and mesentery fat pads) (F) were normalized by the body weight (n = 12 for each group). Student's t -test: # P < 0.05 as compared with the saline group; * P < 0.05 as compared with the control ASO group. ANOVA: & P < 0.05 between the means of the three treatment groups.CC-BY · From the PDF
Fig. 2 FMO3 knockdown in LDLRKO mice leads to decreased atherosclerotic lesion development. A: Atherosclerotic lesion size at the aortic root region of mice treated with saline, control ASO, or FMO3 ASO and fed the Western diet are shown. N = 11 for each group. Symbols are the same as Fig. 1 . B: Macrophage content in the atherosclerotic lesions of the aortic root region was determined by immunohistochemistry using antibodies against CD68. Four mice from each group with three lesion sections per mouse were used in the comparison.
Fig. 2 FMO3 knockdown in LDLRKO mice leads to decreased atherosclerotic lesion development. A: Atherosclerotic lesion size at the aortic root region of mice treated with saline, control ASO, or FMO3 ASO and fed the Western diet are shown. N = 11 for each group. Symbols are the same as Fig. 1 . B: Macrophage content in the atherosclerotic lesions of the aortic root region was determined by immunohistochemistry using antibodies against CD68. Four mice from each group with three lesion sections per mouse were used in the comparison.CC-BY · From the PDF
Fig. 3 Altered plasma lipoprotein profi le in FMO3 ASO-treated LDLRKO mice fed a Western diet. FPLC was used to fractionate pooled plasma samples (fi ve individual samples per pool) from LDLRKO mice treated with the control ASO or the FMO3 ASO and fed the Western diet. TG (A), TC (B), and phosphatidylcholine (C) concentrations of each FPLC fraction were measured and shown.
Fig. 3 Altered plasma lipoprotein profi le in FMO3 ASO-treated LDLRKO mice fed a Western diet. FPLC was used to fractionate pooled plasma samples (fi ve individual samples per pool) from LDLRKO mice treated with the control ASO or the FMO3 ASO and fed the Western diet. TG (A), TC (B), and phosphatidylcholine (C) concentrations of each FPLC fraction were measured and shown.CC-BY · From the PDF
Fig. 4 FMO3 knockdown in LDLRKO mice is associated with increased levels of hepatotoxicity markers and bile acids and decreased levels of urea in the blood. Plasma ALT (A), plasma AST (B), plasma total bile acid (C), plasma urea (D), and plasma IL-6 (E) concentrations are shown. For A-E, n = 10 to 12 per group. Symbols are the same as in Fig. 1 .
Fig. 4 FMO3 knockdown in LDLRKO mice is associated with increased levels of hepatotoxicity markers and bile acids and decreased levels of urea in the blood. Plasma ALT (A), plasma AST (B), plasma total bile acid (C), plasma urea (D), and plasma IL-6 (E) concentrations are shown. For A-E, n = 10 to 12 per group. Symbols are the same as in Fig. 1 .CC-BY · From the PDF
Fig. 5 FMO3 knockdown in LDLRKO mice leads to altered hepatic glucose and lipid levels, altered hepatic gene expression, and changes in plasma metabolites. Liver TG (A), TC (B), phosphatidylcholine (C), glucose (D), and glycogen (E) levels were determined in LDLRKO mice treated with saline, control ASO, or FMO3 ASO and fed the Western diet (n = 8 for each group). F: Liver mRNA levels (n = 6 for each group) of genes involved in lipid and glucose metabolism were quantifi ed by quantitative PCR and normalized by the mRNA level of the housekeeping gene, Rpl13a . In a separate set of mice, circulating levels of amino acids (G), glucose (H), 𝛃 -hydroxybutyrate (I), and glucagon (J) were determined (n = 10 for each group). Symbols are the same as in Fig. 1 .
Fig. 5 FMO3 knockdown in LDLRKO mice leads to altered hepatic glucose and lipid levels, altered hepatic gene expression, and changes in plasma metabolites. Liver TG (A), TC (B), phosphatidylcholine (C), glucose (D), and glycogen (E) levels were determined in LDLRKO mice treated with saline, control ASO, or FMO3 ASO and fed the Western diet (n = 8 for each group). F: Liver mRNA levels (n = 6 for each group) of genes involved in lipid and glucose metabolism were quantifi ed by quantitative PCR and normalized by the mRNA level of the housekeeping gene, Rpl13a . In a separate set of mice, circulating levels of amino acids (G), glucose (H), 𝛃 -hydroxybutyrate (I), and glucagon (J) were determined (n = 10 for each group). Symbols are the same as in Fig. 1 .CC-BY · From the PDF
Image 6
CC-BY · From the PDF
Fig. 7 FMO3 knockdown in C57BL/6J mice fed a chow diet leads to decreased liver TG and fatty acid concentrations and a decreased rate of secretion of VLDL-TG. Female C57BL/6J mice were treated with control or FMO3 ASO for 13 weeks before liver concentrations of TG, TC, and phosphatidylcholine (PC) (A), and the rate of VLDL-TG secretion (B) were determined (n = 8 for each group). In a separate study, the levels of saturated fatty acids (C) and unsaturated fatty acids (D) in the livers of C57BL/6J mice treated with fi ve weekly injections of control or FMO3 ASO were determined by mass spectrometry (n = 4 for each group). Student's t -test: * P < 0.05 as compared with the control ASO group.
Fig. 7 FMO3 knockdown in C57BL/6J mice fed a chow diet leads to decreased liver TG and fatty acid concentrations and a decreased rate of secretion of VLDL-TG. Female C57BL/6J mice were treated with control or FMO3 ASO for 13 weeks before liver concentrations of TG, TC, and phosphatidylcholine (PC) (A), and the rate of VLDL-TG secretion (B) were determined (n = 8 for each group). In a separate study, the levels of saturated fatty acids (C) and unsaturated fatty acids (D) in the livers of C57BL/6J mice treated with fi ve weekly injections of control or FMO3 ASO were determined by mass spectrometry (n = 4 for each group). Student's t -test: * P < 0.05 as compared with the control ASO group.CC-BY · From the PDF
Fig. 8 FMO3 overexpression in Tg mice infl uences liver FMO activity, plasma TMAO, hepatic lipid content, bile acid pool size and composition, body weight, adiposity, and atherosclerotic lesion size. FMO3 Tg/E3L Tg and E3L Tg mice were fed the HF/HC diet for 16 weeks prior to tissue collection. Liver FMO activity (n = 7 for each group) and plasma TMA and TMAO levels (n = 8 to 11 for each group) (A); hepatic levels (n = 10 for each group) of TG, TC, and phosphatidylcholine (PC) (B); and bile acid (BA) pool size and composition (n = 7 to 10 for each group) (C) were measured. For bile acid composition, only the major ( ⩾ 0.5% of total amount) bile acid species are plotted. Body weight (D) and percent weight (E) of four fat pads (gonadal, retroperitoneal, subcutaneous, and mesentery fat pads), normalized by the body weight, were determined (n = 9 to 12 for each group). F: Mean atherosclerotic lesion sizes at the aortic root region were quantifi ed (n = 15 for E3L Tg, n = 31 for FMO3 Tg/E3L Tg). The lesion data were logarithmically transformed for the t -test. Student's t -test: * P < 0.05 as compared with the E3L Tg mice.
Fig. 8 FMO3 overexpression in Tg mice infl uences liver FMO activity, plasma TMAO, hepatic lipid content, bile acid pool size and composition, body weight, adiposity, and atherosclerotic lesion size. FMO3 Tg/E3L Tg and E3L Tg mice were fed the HF/HC diet for 16 weeks prior to tissue collection. Liver FMO activity (n = 7 for each group) and plasma TMA and TMAO levels (n = 8 to 11 for each group) (A); hepatic levels (n = 10 for each group) of TG, TC, and phosphatidylcholine (PC) (B); and bile acid (BA) pool size and composition (n = 7 to 10 for each group) (C) were measured. For bile acid composition, only the major ( ⩾ 0.5% of total amount) bile acid species are plotted. Body weight (D) and percent weight (E) of four fat pads (gonadal, retroperitoneal, subcutaneous, and mesentery fat pads), normalized by the body weight, were determined (n = 9 to 12 for each group). F: Mean atherosclerotic lesion sizes at the aortic root region were quantifi ed (n = 15 for E3L Tg, n = 31 for FMO3 Tg/E3L Tg). The lesion data were logarithmically transformed for the t -test. Student's t -test: * P < 0.05 as compared with the E3L Tg mice.CC-BY · From the PDF
Fig. 9 FMO3 overexpression in Hep3B cells leads to increased glucose production and lipogenesis. Hep3B cells were infected with Ad-CMV or Ad-FMO3 for 2 days, and FMO3 protein levels (n = 4 for each group, left panel) and FMO activity (n = 3 for each group, right panel) (A), glucose secretion rates (B), lipogenesis rates (C), and mRNA levels (D) were measured. For B-D, n = 4 to 6 for each group. Student's t -test: * P < 0.05, ** P < 0.01, and *** P < 0.0001 as compared with the Ad-CMV group, respectively.
Fig. 9 FMO3 overexpression in Hep3B cells leads to increased glucose production and lipogenesis. Hep3B cells were infected with Ad-CMV or Ad-FMO3 for 2 days, and FMO3 protein levels (n = 4 for each group, left panel) and FMO activity (n = 3 for each group, right panel) (A), glucose secretion rates (B), lipogenesis rates (C), and mRNA levels (D) were measured. For B-D, n = 4 to 6 for each group. Student's t -test: * P < 0.05, ** P < 0.01, and *** P < 0.0001 as compared with the Ad-CMV group, respectively.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 342

Metadata

Authors
Shih, D. M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., Qi, H., Wu, J., Pan, C., Brown, J. M., Vallim, T., Bennett, B. J., Graham, M., Hazen, S. L., & Lusis, A. J.
Affiliations
  • University of California, Los Angeles (US)
  • Cleveland Clinic (US)
  • Ionis Pharmaceuticals (United States) (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Lusis, Aldons J.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2015-01
Volume
56
Issue
1
Pages
22-37
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2163604084
Cited by
335
References
46
Citations by year
2026: 17 · 2025: 19 · 2024: 18 · 2023: 20 · 2022: 43 · 2021: 36 · 2020: 44 · 2019: 33 · 2018: 28 · 2017: 28 · 2016: 33 · 2015: 16
FWCI
29.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • UNC Libraries
Funders
  • National Institutes of Health (HL‐28481, HL30568, HL113452)
  • National Heart, Lung, and Blood Institute (HL3 0568, HL28481, P01HL030568, HL113452, P20HL113452, P01HL028481)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
FMO3, trimethylamine N-oxide, atherosclerosis, glucose metabolism, lipid metabolism, hepatic lipogenesis, gluconeogenesis, PPARα, KLF15, hyperlipidemia, LDL receptor knockout mice, hepatic lipid accumulation, insulin, ketone bodies
MeSH terms
Animals, Bile Acids and Salts, DNA-Binding Proteins, Feces, Female, Glucose, Homeostasis, Humans, Insulin, Intestinal Mucosa, Lipoproteins, Liver, Methylamines, Oxygenases, Receptors, LDL, Transcription Factors, Gene Expression Regulation, Enzymologic, Cell Line, Tumor, PPAR alpha, Lipogenesis, Atherosclerosis, Lipid Metabolism, Mice, Kruppel-Like Transcription Factors, Gene Knockdown Techniques, Gene Knockout Techniques, Diet, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.